Renmin Tianli Group, Inc. (ABAC) Trades at $2.21 After Triangle; Eventide Asset Management Trimmed By $4.86 Million Its Acadia Pharmaceuticals (ACAD) Position

Eventide Asset Management Llc decreased Acadia Pharmaceuticals Inc (ACAD) stake by 66.06% reported in 2018Q1 SEC filing. Eventide Asset Management Llc sold 221,100 shares as Acadia Pharmaceuticals Inc (ACAD)’s stock declined 45.28%. The Eventide Asset Management Llc holds 113,600 shares with $2.55 million value, down from 334,700 last quarter. Acadia Pharmaceuticals Inc now has $2.04 billion valuation. The stock increased 2.38% or $0.38 during the last trading session, reaching $16.33. About 3.48M shares traded or 2.56% up from the average. ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) has declined 32.66% since June 24, 2017 and is downtrending. It has underperformed by 45.23% the S&P500. Some Historical ACAD News: 15/05/2018 – Healthcor Management Buys New 1.1% Position in Acadia Pharma; 09/04/2018 – Some lingering concerns about $ACAD ‘s Nuplazid are resurfacing this morning in CNN investigation. Could be real trouble. #FDA on thin ice too; 23/04/2018 – PMDAlliance and ACADIA Pharmaceuticals Survey Reveals Serious Quality-of-Life Impact of Non-Movement Symptoms of Parkinson’s Disease; 27/04/2018 – ACADIA Pharmaceuticals Issues Statement Reaffirming Benefit/Risk Profile of NUPLAZID; 04/05/2018 – ACADIA PHARMA 1Q REV. $48.9M, EST. $47.1M; 04/05/2018 – ACADIA Pharmaceuticals 1Q Research and Development Expenses $39.3 Million; 14/05/2018 – Acadia Pharma Presenting at Bank of America Conference Tomorrow; 08/05/2018 – Acadia Pharma Presenting at Conference May 15; 04/05/2018 – ACADIA PHARMACEUTICALS INC ACAD.O FY2018 REV VIEW $269.3 MLN — THOMSON REUTERS l/B/E/S; 12/04/2018 – Interior-Parks: Mud Season Closure of Acadia Carriage Roads

Renmin Tianli Group, Inc. (ABAC) formed triangle with $2.36 target or 7.00% above today’s $2.21 share price. Renmin Tianli Group, Inc. (ABAC) has $22.06 million valuation. The stock decreased 1.78% or $0.04 during the last trading session, reaching $2.21. About 9,511 shares traded. Renmin Tianli Group, Inc. (NASDAQ:ABAC) has risen 16.92% since June 24, 2017 and is uptrending. It has outperformed by 4.35% the S&P500.

Since January 2, 2018, it had 1 insider buy, and 3 selling transactions for $3.94 million activity. The insider Baity Glenn sold $2.24M. The insider Brege Laura sold 25,000 shares worth $751,543. SOLAND DANIEL B also bought $234,910 worth of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) shares.

Among 12 analysts covering ACADIA Pharmaceuticals (NASDAQ:ACAD), 9 have Buy rating, 0 Sell and 3 Hold. Therefore 75% are positive. ACADIA Pharmaceuticals had 35 analyst reports since August 7, 2015 according to SRatingsIntel. Piper Jaffray downgraded the stock to “Neutral” rating in Friday, August 7 report. The stock of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) earned “Buy” rating by Bank of America on Tuesday, November 8. The stock of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) earned “Buy” rating by Jefferies on Tuesday, October 10. The rating was maintained by Needham on Tuesday, April 10 with “Buy”. Piper Jaffray maintained ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) on Wednesday, August 9 with “Buy” rating. The rating was maintained by Cowen & Co on Tuesday, April 10 with “Buy”. As per Tuesday, May 3, the company rating was downgraded by Leerink Swann. Vetr upgraded ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) on Monday, August 10 to “Hold” rating. Cowen & Co maintained ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) rating on Wednesday, October 4. Cowen & Co has “Buy” rating and $46.0 target. Piper Jaffray upgraded ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) rating on Thursday, August 27. Piper Jaffray has “Neutral” rating and $48.0 target.

Analysts await ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) to report earnings on August, 14. They expect $-0.46 earnings per share, up 16.36% or $0.09 from last year’s $-0.55 per share. After $-0.44 actual earnings per share reported by ACADIA Pharmaceuticals Inc. for the previous quarter, Wall Street now forecasts 4.55% negative EPS growth.

Eventide Asset Management Llc increased Wen Hldg Inc stake by 137,600 shares to 644,100 valued at $19.72 million in 2018Q1. It also upped Sunopta Inc (NASDAQ:STKL) stake by 398,515 shares and now owns 4.30M shares. Kalvista Pharmaceuticals Inc was raised too.

Investors sentiment decreased to 0.89 in Q1 2018. Its down 0.37, from 1.26 in 2017Q4. It turned negative, as 24 investors sold ACAD shares while 59 reduced holdings. 21 funds opened positions while 53 raised stakes. 119.37 million shares or 1.72% more from 117.35 million shares in 2017Q4 were reported. Jane Street Group owns 13,393 shares. Citadel Ltd Limited Liability Company accumulated 41,080 shares. Schwab Charles holds 446,291 shares or 0.01% of its portfolio. Daiwa Secs Group reported 73,295 shares. Fincl Architects holds 920 shares or 0% of its portfolio. Utah Retirement System owns 18,300 shares for 0.01% of their portfolio. Barclays Public Ltd accumulated 66,111 shares. Pictet Asset Mngmt Limited owns 701,833 shares for 0.04% of their portfolio. Tci Wealth Advisors reported 1,500 shares stake. Utd Services Automobile Association invested 0% in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD). Da Davidson invested 0.01% of its portfolio in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD). Qvt Financial Limited Partnership holds 0.07% of its portfolio in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) for 28,736 shares. Sectoral Asset Mgmt invested in 783,424 shares or 1.93% of the stock. Amalgamated Financial Bank reported 21,021 shares stake. Victory Cap Mngmt Inc stated it has 0% in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD).

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Institutional Positions Chart